Endothelins and carcinogenesis

• Main Authors: Jacek Olender, Ewa Nowakowska-Zajdel, Katarzyna Walkiewicz, Małgorzata Muc-Wierzgoń
• Format: Article
• Language: English
• Published: Index Copernicus International S.A. 2016-08-01
• Series: Postępy Higieny i Medycyny Doświadczalnej
• Subjects: endoteliny; receptory endotelinowe; nowotworzenie; Endothelins; endothelin receptor; carcinogenesis
• Online Access: http://phmd.pl/gicid/01.3001.0009.6865

Endothelins are a family of four endogenous peptides (ET-1, ET-2, ET-3, ET-4) secreted primarily in an inactive form by the endothelium. They are activated with the participation of converting enzyme. Numerous studies have described their pleiotropic biological activity. These peptides are involved, inter alia, in the regulation of processes such as cell proliferation, migration, angiogenesis and apoptosis. Their important role in the regulation of blood pressure, tissue perfusion (especially in the central nervous system), and myocardial systolic function is also known. Moreover, changes in transcriptional activity of endothelin and its receptors may be involved, with the participation of a number of signaling pathways, in carcinogenesis, and the pathogenesis of numerous diseases (heart, kidney, lung and skin disorders, especially with the component of fibrosis). Their role has been documented in the development of breast, prostatic, colorectal, ovarian, lung, kidney, and endometrial cancer, and in melanoma. In this article we present a brief description of the endothelin group and the participation of them and their receptors in carcinogenesis. We also try to show their role as prognostic and predictive factors in human malignant tumors. The article also refers to clinical trials on the use of preparations of endothelin receptor antagonists in the design of molecular therapeutic strategies in human malignancies.